SCHEMBL3553199

SCHEMBL3553199

O=C(c1ccc(I)cc1)c1ccc2nc(Cl)nc(-c3cccc(Cl)c3)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 2/20 0.45
CSNK2B P67870 2/20 0.45
KDM4E B2RXH2 3/20 0.43
LMNA P02545 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 2/20 0.42
OPRK1 P41145 1/20 0.42
RORB Q92753 2/20 0.41
PDE4A P27815 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
BACE1 P56817 1/20 0.38
KMO O15229 1/20 0.36
HPD P32754 2/20 0.36
PTGFR P43088 1/20 0.36
HTT P42858 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14039064 0.92 CSNK2A2 (0.47) CSNK2A2CSNK2BKDM4ELMNAALDH1A1
SCHEMBL3559214 0.88 CSNK2A2 (0.45) CSNK2A2CSNK2BKDM4ELMNAALDH1A1
SCHEMBL3553323 0.88 KDM4E (0.55) CSNK2A2CSNK2BKDM4ELMNAALDH1A1
SCHEMBL3557898 0.85 HPGD (0.46) CSNK2A2CSNK2BKDM4ELMNAALDH1A1
SCHEMBL5658696 0.83 MAT2A (0.42) CSNK2A2CSNK2BKDM4ELMNAALDH1A1
SCHEMBL5548743 0.83 DOT1L (0.55) CSNK2A2CSNK2BKDM4ELMNAALDH1A1
SCHEMBL5658645 0.81 NPC1 (0.47) CSNK2A2CSNK2BKDM4ELMNAALDH1A1
SCHEMBL5023267 0.81 CSNK2A2 (0.43) CSNK2A2CSNK2BKDM4ELMNAALDH1A1
SCHEMBL5782688 0.80 CSNK2A2 (0.46) CSNK2A2CSNK2BKDM4ERORBHPD
SCHEMBL5654518 0.79 KDM4E (0.55) CSNK2A2CSNK2BKDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655654-B2 Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles JANSSEN PHARMACEUTICA NV (BE) 2010-02-02 US disclosed
US-7511138-B2 Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles JANSSEN PHARMACEUTICA NV (BE) 2009-03-31 US disclosed
US-7501538-B2 Aryl and heteroaryl compounds, compositions and methods of use TRANSTECH PHARMA, INC. (US) 2009-03-10 US disclosed
US-20080027086-A1 FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES ANGIBAUD PATRICK R 2008-01-31 US disclosed
US-7173040-B2 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-06 US disclosed
EP-1497295-B1 FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES JANSSEN PHARMACEUTICA NV (BE) 2006-08-16 EP disclosed
US-20050148609-A1 Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles of triazoles JANSSEN PHARMACEUTICA, N.V. (BE) 2005-07-07 US disclosed
US-20050049310-A1 Aryl and heteroaryl compounds, compositions and methods of use VTVX HOLDINGS I LLC 2005-03-03 US disclosed
EP-1497295-A1 FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2005-01-19 EP disclosed
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties JANSSEN-CILAG S.A. (FR) 2004-03-11 US disclosed
WO-2003087101-A1 FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2003-10-23 WO disclosed
EP-1322636-A1 FARNESYL TRANSFERASE INHIBITING 6- (SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024683-A1 FARNESYL TRANSFERASE INHIBITING 6-[(SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties FNTB, FNTA, CYP7A1 CSNK2A2 2798/4885CSNK2B 2717/4885KDM4E 1592/4885
US-20050049310-A1 Aryl and heteroaryl compounds, compositions and methods of use EPOR, HBG2, CYP2F1 CSNK2A2 823/4885CSNK2B 1027/4885KDM4E 2327/4885
US-20050148609-A1 Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles of triazoles FNTA, FNTB, HCCS CSNK2A2 1605/4885CSNK2B 1778/4885KDM4E 3109/4885
US-20080027086-A1 FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES FNTA, FNTB, CYP7A1 CSNK2A2 1731/4885CSNK2B 1875/4885KDM4E 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.